Program
SYH2053
A development code. Also written as “SYH2053 Injection” and “SYH2053 injection”.
Its studies are mostly in Hyperlipoproteinemia Type II · Renal Insufficiency · Hyperlipidemias, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 43 open or running | phase 3since Feb 12, 2026 | Dec 20, 2023 | Jul 15, 2027phase 1 · NCT07938034 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
SYH2053 (PCSK9 siRNA)
, phase 3, as of Aug 20, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2023First study: phase 1 study in HyperlipidemiasFirst studyNCT06229548 · 39 enrolled · China
- Feb 12, 2026Phase 3 study in Hyperlipoproteinemia Type IIPhase 3 reachedNCT07421297 · 760 planned · China
- Mar 6, 2026Phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07465263 · 135 planned · China
- Jul 2, 2026Phase 1 study in Renal InsufficiencyNCT07938034 · 24 planned · China
Ahead
- Jul 15, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07938034
- Dec 31, 2027Primary completion: phase 3 study in Hyperlipoproteinemia Type IINCT07421297
- Feb 28, 2028Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07465263
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07938034Renal Insufficiency · China | 1 | Recruiting | Jul 15, 2027 | 24 |
| NCT07465263Heterozygous Familial Hypercholesterolemia (HeFH) · China | 3 | Recruiting | Feb 28, 2028 | 135 |
| NCT07421297Hyperlipoproteinemia Type II · China | 3 | Recruiting | Dec 31, 2027 | 760 |
| NCT06229548Hyperlipidemias · China | 1 | Completed | Dec 23, 2024 | 39 |
How it is read
Names in the registry
- “SYH2053”, 2 entries
- “SYH2053 Injection”, 1 entry
- “SYH2053 injection”, 1 entry
Codes read as this program: SYH2053.
Conditions, from the studies’ own filings
- Hyperlipoproteinemia Type II, 2 studies
- Renal Insufficiency, 1 study
- Hyperlipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.